{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T00:00:17Z","timestamp":1771545617871,"version":"3.50.1"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,3,25]],"date-time":"2025-03-25T00:00:00Z","timestamp":1742860800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,3,25]],"date-time":"2025-03-25T00:00:00Z","timestamp":1742860800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Henan Province Medical Science and Technology Project Joint Construction","award":["LHGJ20200485"],"award-info":[{"award-number":["LHGJ20200485"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Indian J Hematol Blood Transfus"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1007\/s12288-025-02004-z","type":"journal-article","created":{"date-parts":[[2025,3,27]],"date-time":"2025-03-27T16:23:23Z","timestamp":1743092603000},"page":"530-541","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["SAR317461 Inhibit JAK2\/STAT3 Phosphorylation for Enhanced Anti-leukemia Activity"],"prefix":"10.1007","volume":"42","author":[{"given":"Xiao-Yu","family":"Yang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Su-Lei","family":"Pang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiao-Jie","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pan-Pan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruo-Jin","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yun-Yun","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chun-Ge","family":"Song","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,3,25]]},"reference":[{"issue":"1","key":"2004_CR1","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1038\/s41392-020-0110-5","volume":"5","author":"L Yang","year":"2020","unstructured":"Yang L, Shi P, Zhao G, Xu J, Peng W, Zhang J, Zhang G, Wang X, Dong Z, Chen F et al (2020) Targeting cancer stem cell pathways for cancer therapy. Signal Transduct Target Therapy 5(1):8","journal-title":"Signal Transduct Target Therapy"},{"issue":"26","key":"2004_CR2","doi-asserted-by":"publisher","first-page":"4422","DOI":"10.1200\/JCO.2008.21.3264","volume":"27","author":"M Benekli","year":"2009","unstructured":"Benekli M, Baumann H, Wetzler M (2009) Targeting signal transducer and activator of transcription signaling pathway in leukemias. J Clin Oncology: Official J Am Soc Clin Oncol 27(26):4422\u20134432","journal-title":"J Clin Oncology: Official J Am Soc Clin Oncol"},{"issue":"13","key":"2004_CR3","doi-asserted-by":"publisher","first-page":"3000","DOI":"10.1182\/bloodadvances.2019001292","volume":"4","author":"J Habbel","year":"2020","unstructured":"Habbel J, Arnold L, Chen Y, M\u00f6llmann M, Bruderek K, Brandau S, D\u00fchrsen U, Hanoun M (2020) Inflammation-driven activation of JAK\/STAT signaling reversibly accelerates acute myeloid leukemia in vitro. Blood Adv 4(13):3000\u20133010","journal-title":"Blood Adv"},{"key":"2004_CR4","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.ebiom.2017.11.013","volume":"26","author":"II Nitulescu","year":"2017","unstructured":"Nitulescu II, Meyer SC, Wen QJ, Crispino JD, Lemieux ME, Levine RL, Pelish HE, Shair MD (2017) Mediator kinase phosphorylation of STAT1 S727 promotes growth of neoplasms with JAK-STAT activation. EBioMedicine 26:112\u2013125","journal-title":"EBioMedicine"},{"issue":"6","key":"2004_CR5","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1182\/blood-2016-02-699363","volume":"130","author":"R Karjalainen","year":"2017","unstructured":"Karjalainen R, Pemovska T, Popa M, Liu M, Javarappa KK, Majumder MM, Yadav B, Tamborero D, Tang J, Bychkov D et al (2017) JAK1\/2 and BCL2 inhibitors synergize to counteract bone marrow stromal cell-induced protection of AML. Blood 130(6):789\u2013802","journal-title":"Blood"},{"key":"2004_CR6","doi-asserted-by":"crossref","unstructured":"Moser B, Edtmayer S, Witalisz-Siepracka A, Stoiber D (2021) The ups and downs of STAT Inhibition in acute myeloid leukemia. Biomedicines 9(8)","DOI":"10.3390\/biomedicines9081051"},{"key":"2004_CR7","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1186\/s12967-015-0627-5","volume":"13","author":"R Mukthavaram","year":"2015","unstructured":"Mukthavaram R, Ouyang X, Saklecha R, Jiang P, Nomura N, Pingle SC, Guo F, Makale M, Kesari S (2015) Effect of the JAK2\/STAT3 inhibitor SAR317461 on human glioblastoma tumorspheres. J Translational Med 13:269","journal-title":"J Translational Med"},{"issue":"36","key":"2004_CR8","doi-asserted-by":"publisher","first-page":"37901","DOI":"10.1021\/acsomega.4c00710","volume":"9","author":"Y Zuo","year":"2024","unstructured":"Zuo Y, Li H, Wang X, Liang Y, Huang C, Nai G, Ruan J, Dong W, Lu X (2024) Inhibition of JAK\/STAT3 expression by acute myeloid Leukemia-Targeted nanoliposome for chemotherapy enhancement. ACS Omega 9(36):37901\u201337909","journal-title":"ACS Omega"},{"key":"2004_CR9","doi-asserted-by":"crossref","unstructured":"Ou A, Ott M, Fang D, Heimberger AB (2021) The role and therapeutic targeting of JAK\/STAT signaling in glioblastoma. Cancers 13(3)","DOI":"10.3390\/cancers13030437"},{"key":"2004_CR10","doi-asserted-by":"crossref","unstructured":"Piperi C, Papavassiliou KA, Papavassiliou AG (2019) Pivotal role of STAT3 in shaping glioblastoma immune microenvironment. Cells 8(11)","DOI":"10.3390\/cells8111398"},{"issue":"3","key":"2004_CR11","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1007\/s10787-021-00813-y","volume":"29","author":"NP Nailwal","year":"2021","unstructured":"Nailwal NP, Doshi GM (2021) Role of intracellular signaling pathways and their inhibitors in the treatment of inflammation. Inflammopharmacology 29(3):617\u2013640","journal-title":"Inflammopharmacology"},{"key":"2004_CR12","doi-asserted-by":"crossref","unstructured":"Moore JA, Mistry JJ, Hellmich C, Horton RH, Wojtowicz EE, Jibril A, Jefferson M, Wileman T, Beraza N, Bowles KM et al (2022) LC3-associated phagocytosis in bone marrow macrophages suppresses acute myeloid leukemia progression through STING activation. J Clin Investig 132(5)","DOI":"10.1172\/JCI153157"},{"key":"2004_CR13","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.yjmcc.2019.09.001","volume":"136","author":"Y Dong","year":"2019","unstructured":"Dong Y, Chen H, Gao J, Liu Y, Li J, Wang J (2019) Molecular machinery and interplay of apoptosis and autophagy in coronary heart disease. J Mol Cell Cardiol 136:27\u201341","journal-title":"J Mol Cell Cardiol"},{"issue":"2","key":"2004_CR14","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1056\/NEJMra1202117","volume":"368","author":"JJ O\u2019Shea","year":"2013","unstructured":"O\u2019Shea JJ, Holland SM, Staudt LM (2013) JAKs and stats in immunity, immunodeficiency, and cancer. N Engl J Med 368(2):161\u2013170","journal-title":"N Engl J Med"},{"issue":"7","key":"2004_CR15","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1038\/nsmb.2849","volume":"21","author":"Y Shan","year":"2014","unstructured":"Shan Y, Gnanasambandan K, Ungureanu D, Kim ET, Hammar\u00e9n H, Yamashita K, Silvennoinen O, Shaw DE, Hubbard SR (2014) Molecular basis for pseudokinase-dependent autoinhibition of JAK2 tyrosine kinase. Nat Struct Mol Biol 21(7):579\u2013584","journal-title":"Nat Struct Mol Biol"},{"key":"2004_CR16","doi-asserted-by":"publisher","first-page":"100634","DOI":"10.1016\/j.blre.2019.100634","volume":"40","author":"S Venugopal","year":"2020","unstructured":"Venugopal S, Bar-Natan M, Mascarenhas JO (2020) JAKs to stats: A tantalizing therapeutic target in acute myeloid leukemia. Blood Rev 40:100634","journal-title":"Blood Rev"},{"issue":"2","key":"2004_CR17","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1038\/s41375-018-0357-9","volume":"33","author":"N Daver","year":"2019","unstructured":"Daver N, Schlenk RF, Russell NH, Levis MJ (2019) Targeting FLT3 mutations in AML: review of current knowledge and evidence. Leukemia 33(2):299\u2013312","journal-title":"Leukemia"},{"key":"2004_CR18","doi-asserted-by":"crossref","unstructured":"Brachet-Botineau M, Polomski M, Neubauer HA, Juen L, H\u00e9dou D, Viaud-Massuard MC, Pri\u00e9 G, Gouilleux F (2020) Pharmacological Inhibition of oncogenic STAT3 and STAT5 signaling in hematopoietic cancers. Cancers 12(1)","DOI":"10.3390\/cancers12010240"},{"issue":"25","key":"2004_CR19","doi-asserted-by":"publisher","first-page":"3742","DOI":"10.1038\/sj.onc.1202708","volume":"18","author":"M Kortylewski","year":"1999","unstructured":"Kortylewski M, Heinrich PC, Mackiewicz A, Schniertshauer U, Klingm\u00fcller U, Nakajima K, Hirano T, Horn F, Behrmann I (1999) Interleukin-6 and Oncostatin M-induced growth Inhibition of human A375 melanoma cells is STAT-dependent and involves upregulation of the cyclin-dependent kinase inhibitor p27\/Kip1. Oncogene 18(25):3742\u20133753","journal-title":"Oncogene"},{"issue":"1","key":"2004_CR20","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/0014-5793(96)01069-1","volume":"396","author":"JA Philp","year":"1996","unstructured":"Philp JA, Burdon TG, Watson CJ (1996) Differential activation of stats 3 and 5 during mammary gland development. FEBS Lett 396(1):77\u201380","journal-title":"FEBS Lett"},{"issue":"24","key":"2004_CR21","doi-asserted-by":"publisher","first-page":"3797","DOI":"10.1182\/blood-2013-10-534073","volume":"123","author":"U Rozovski","year":"2014","unstructured":"Rozovski U, Wu JY, Harris DM, Liu Z, Li P, Hazan-Halevy I, Ferrajoli A, Burger JA, O\u2019Brien S, Jain N et al (2014) Stimulation of the B-cell receptor activates the JAK2\/STAT3 signaling pathway in chronic lymphocytic leukemia cells. Blood 123(24):3797\u20133802","journal-title":"Blood"},{"issue":"2","key":"2004_CR22","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1038\/nrc1275","volume":"4","author":"H Yu","year":"2004","unstructured":"Yu H, Jove R (2004) The stats of cancer\u2013new molecular targets come of age. Nat Rev Cancer 4(2):97\u2013105","journal-title":"Nat Rev Cancer"},{"issue":"9","key":"2004_CR23","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1002\/ajh.21785","volume":"85","author":"V Ramakrishnan","year":"2010","unstructured":"Ramakrishnan V, Kimlinger T, Haug J, Timm M, Wellik L, Halling T, Pardanani A, Tefferi A, Rajkumar SV, Kumar S (2010) TG101209, a novel JAK2 inhibitor, has significant in vitro activity in multiple myeloma and displays Preferential cytotoxicity for CD45\u2009+\u2009myeloma cells. Am J Hematol 85(9):675\u2013686","journal-title":"Am J Hematol"},{"key":"2004_CR24","doi-asserted-by":"crossref","unstructured":"O\u2019Shea JJ, Plenge RJI (2012) JAK and STAT signaling molecules in immunoregulation and immune-mediated disease. 36(4):542\u2013550","DOI":"10.1016\/j.immuni.2012.03.014"},{"key":"2004_CR25","doi-asserted-by":"crossref","unstructured":"Ghoreschi K, Laurence A, O\u2019Shea, JJJIr (2009) Janus kinases in immune cell signaling. 228(1):273\u2013287","DOI":"10.1111\/j.1600-065X.2008.00754.x"},{"key":"2004_CR26","doi-asserted-by":"crossref","unstructured":"Verstovsek S, Kantarjian H, Mesa RA, Pardanani AD, Cortes-Franco J, Thomas DA, Estrov Z, Fridman JS, Bradley EC (2010) Erickson-Viitanen SJNEJoM: safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. 363(12):1117\u20131127","DOI":"10.1056\/NEJMoa1002028"},{"key":"2004_CR27","doi-asserted-by":"crossref","unstructured":"Zhou T, Georgeon S, Moser R, Moore D, Caflisch A, Hantschel OJL (2014) Specificity and mechanism-of-action of the JAK2 tyrosine kinase inhibitors ruxolitinib and SAR302503 (TG101348). 28(2):404\u2013407","DOI":"10.1038\/leu.2013.205"},{"key":"2004_CR28","doi-asserted-by":"crossref","unstructured":"Guimar\u00e3es PO, Damiani LP, Tavares CAM, Halpern ASR, Deuring JJ, Rizzo LV (2024) Berwanger OJe: laboratory profiles of patients hospitalized with COVID-19 pneumonia treated with Tofacitinib or placebo: a post hoc analysis from the STOP-COVID trial. 22:eAO0821","DOI":"10.31744\/einstein_journal\/2024AO0821"},{"key":"2004_CR29","doi-asserted-by":"crossref","unstructured":"Simpson EL, Silverberg JI, Nosbaum A, Winthrop K, Guttman-Yassky E, Hoffmeister KM, Egeberg A, Valdez H, Fan H (2024) Farooqui SAJAJoCD: integrated safety update of abrocitinib in 3802 patients with Moderate-to-Severe atopic dermatitis: data from more than 5200 Patient-Years with up to 4 years of exposure.:1\u201316","DOI":"10.1007\/s40257-024-00869-w"},{"key":"2004_CR30","doi-asserted-by":"crossref","unstructured":"Perner F, Perner C, Ernst T, Heidel FHJC (2019) Roles of JAK2 in aging, inflammation, hematopoiesis and malignant transformation. 8(8):854","DOI":"10.3390\/cells8080854"},{"key":"2004_CR31","doi-asserted-by":"publisher","first-page":"1135145","DOI":"10.3389\/fphar.2023.1135145","volume":"14","author":"NK Jain","year":"2023","unstructured":"Jain NK, Tailang M, Jain HK, Chandrasekaran B, Sahoo BM, Subramanian A, Thangavel N, Aldahish A, Chidambaram K, Alagusundaram M et al (2023) Therapeutic implications of current Janus kinase inhibitors as anti-COVID agents: A review. Front Pharmacol 14:1135145","journal-title":"Front Pharmacol"},{"issue":"6","key":"2004_CR32","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1007\/s00203-023-03559-z","volume":"205","author":"J Narayanan","year":"2023","unstructured":"Narayanan J, Tamilanban T, Kumar PS, Guru A, Muthupandian S, Kathiravan MK, Arockiaraj J (2023) Role and mechanistic actions of protein kinase inhibitors as an effective drug target for cancer and COVID. Arch Microbiol 205(6):238","journal-title":"Arch Microbiol"},{"issue":"8","key":"2004_CR33","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1080\/17425255.2024.2373092","volume":"20","author":"S Chandrashekara","year":"2024","unstructured":"Chandrashekara S (2024) Pharmacokinetic review of Janus kinase inhibitors and its clinical implications for the management of rheumatoid arthritis. Expert Opin Drug Metab Toxicol 20(8):741\u2013748","journal-title":"Expert Opin Drug Metab Toxicol"}],"container-title":["Indian Journal of Hematology and Blood Transfusion"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12288-025-02004-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12288-025-02004-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12288-025-02004-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T23:02:13Z","timestamp":1771542133000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12288-025-02004-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,25]]},"references-count":33,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["2004"],"URL":"https:\/\/doi.org\/10.1007\/s12288-025-02004-z","relation":{},"ISSN":["0971-4502","0974-0449"],"issn-type":[{"value":"0971-4502","type":"print"},{"value":"0974-0449","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,25]]},"assertion":[{"value":"6 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The animal study was reviewed and approved by the Ethics Committee for Experimental Animals of The Fifth Affiliated Hospital of Zhengzhou University.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Statement"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}]}}